Literature DB >> 29417327

Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease: Is the Difference Real?

Tamara Mogilevski1, Miles P Sparrow2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29417327     DOI： 10.1007/s10620-018-4952-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  12 in total

1.  A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.

Authors:  P Varma; E Paul; C Huang; B Headon; M P Sparrow
Journal:  Intern Med J       Date:  2016-07       Impact factor: 2.048

2.  Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study.

Authors:  J D Doecke; F Hartnell; P Bampton; S Bell; G Mahy; Z Grover; P Lewindon; L V Jones; K Sewell; K Krishnaprasad; R Prosser; D Marr; J Fischer; G R Thomas; J V Tehan; N S Ding; S E Cooke; K Moss; A Sechi; P De Cruz; R Grafton; S J Connor; I C Lawrance; R B Gearry; J M Andrews; G L Radford-Smith
Journal:  Aliment Pharmacol Ther       Date:  2016-12-19       Impact factor: 8.171

3.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

4.  Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.

Authors:  F Zorzi; S Zuzzi; S Onali; E Calabrese; G Condino; C Petruzziello; M Ascolani; F Pallone; L Biancone
Journal:  Aliment Pharmacol Ther       Date:  2012-04-22       Impact factor: 8.171

5.  Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

Authors:  W J Sandborn; S B Hanauer; P Rutgeerts; R N Fedorak; M Lukas; D G MacIntosh; R Panaccione; D Wolf; J D Kent; B Bittle; J Li; P F Pollack
Journal:  Gut       Date:  2007-02-13       Impact factor: 23.059

6.  Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.

Authors:  Christine Kestens; Martijn G H van Oijen; Charlotte L J Mulder; Ad A van Bodegraven; Gerard Dijkstra; Dirk de Jong; Cyriel Ponsioen; Bas A C van Tuyl; Peter D Siersema; Herma H Fidder; Bas Oldenburg
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-29       Impact factor: 11.382

7.  Comparative effectiveness of infliximab and adalimumab for Crohn's disease.

Authors:  Mark T Osterman; Kevin Haynes; Elizabeth Delzell; Jie Zhang; Meenakshi Bewtra; Colleen Brensinger; Lang Chen; Fenlong Xie; Jeffrey R Curtis; James D Lewis
Journal:  Clin Gastroenterol Hepatol       Date:  2013-06-28       Impact factor: 11.382

8.  Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.

Authors:  Amine Benmassaoud; Talal Al-Taweel; Mark Solomon Sasson; Dasha Moza; Matthew Strohl; Uri Kopylov; Laurence Paradis-Surprenant; Mohanad Almaimani; Alain Bitton; Waqqas Afif; Peter L Lakatos; Talat Bessissow
Journal:  Dig Dis Sci       Date:  2017-12-14       Impact factor: 3.199

9.  The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.

Authors:  N Narula; S Kainz; W Petritsch; T Haas; T Feichtenschlager; G Novacek; A Eser; H Vogelsang; W Reinisch; P Papay
Journal:  Aliment Pharmacol Ther       Date:  2016-05-26       Impact factor: 8.171

10.  Adalimumab for the treatment of fistulas in patients with Crohn's disease.

Authors:  J-F Colombel; D A Schwartz; W J Sandborn; M A Kamm; G D'Haens; P Rutgeerts; R Enns; R Panaccione; S Schreiber; J Li; J D Kent; K G Lomax; P F Pollack
Journal:  Gut       Date:  2009-02-06       Impact factor: 23.059
View more
  2 in total

1.  Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease.

Authors:  Amber Bangma; Michiel D Voskuil; Werna T C Uniken Venema; Harm Brugge; Shixian Hu; Pauline Lanting; Lude Franke; Gerard Dijkstra; Eleonora A M Festen; Rinse K Weersma
Journal:  Aliment Pharmacol Ther       Date:  2020-05-03       Impact factor: 8.171

2.  Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation.

Authors:  Jiri Bronsky; Ivana Copova; Denis Kazeka; Tereza Lerchova; Katarina Mitrova; Kristyna Pospisilova; Miroslava Sulovcova; Kristyna Zarubova; Ondrej Hradsky
Journal:  Clin Transl Gastroenterol       Date:  2022-05-01       Impact factor: 4.396
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.